XRTX Stock Overview A late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, pre-diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
XORTX Therapeutics Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for XORTX Therapeutics Historical stock prices Current Share Price CA$1.69 52 Week High CA$9.35 52 Week Low CA$1.54 Beta -0.20 1 Month Change -3.98% 3 Month Change -19.52% 1 Year Change -53.95% 3 Year Change -92.64% 5 Year Change -88.97% Change since IPO -96.80%
Recent News & Updates
XORTX Therapeutics Inc. Announces Chief Financial Officer Changes Dec 19
New major risk - Shareholder dilution Oct 20 XORTX Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $1.499994 million. Oct 18
XORTX Therapeutics Inc. Initiates Precision Medicine Program Oct 09 XORTX Therapeutics Inc. announced delayed 20-F filing May 03
XORTX Therapeutics Inc. Appoints Abigail Jenkins to the Board of Directors Apr 09 See more updates
XORTX Therapeutics Inc. Announces Chief Financial Officer Changes Dec 19
New major risk - Shareholder dilution Oct 20 XORTX Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $1.499994 million. Oct 18
XORTX Therapeutics Inc. Initiates Precision Medicine Program Oct 09 XORTX Therapeutics Inc. announced delayed 20-F filing May 03
XORTX Therapeutics Inc. Appoints Abigail Jenkins to the Board of Directors Apr 09
XORTX Therapeutics Inc. Appoints Ronald Perrone as Clinical Advisory Board Mar 27 XORTX Therapeutics Inc. announced a financing transaction Feb 15
High number of new and inexperienced directors Jan 06
XORTX Therapeutics Inc. Announces Board Changes Jan 02
XORTX Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $3.701931 million. Dec 01 XORTX Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $3.701931 million. Nov 30
New major risk - Revenue and earnings growth Nov 07
XORTX Therapeutics Inc. Announces Presentation of New Research Findings At the American Society of Nephrology Meeting Nov 04
XORTX Therapeutics to Consider A Consolidation of the Company’s Issued and Outstanding Shares in Order for the Company to Regain Compliance with the Continued Listing Requirements for the Nasdaq Capital Market Oct 26
XORTX Therapeutics Provides Nasdaq Compliance Update Oct 06
New major risk - Share price stability Oct 05
Xortx Therapeutics Inc. Submits Orphan Drug Designation Application to the European Medicines Agency to Treat Progressive Kidney Disease Aug 30
New major risk - Market cap size Aug 25
New minor risk - Share price stability Aug 22
XORTX Therapeutics Inc. Announces Chief Financial Officer Changes Aug 05 XORTX Therapeutics Inc. Announces Departure of Jacqueline Le Saux
XORTX Therapeutics Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency May 25
XORTX Therapeutics Inc. Announces FDA Confirms Eligibility of XORLO™ for Accelerated Approval May 05
XORTX Therapeutics Inc. Announces Goals for 2023 Feb 08
Xortx Therapeutics Inc. Announces Submission of Orphan Drug Designation Request for Xrx-008 Program to Treat Autosomal Dominant Kidney Disease Feb 02
XORTX Therapeutics Inc. Announces Positive Topline Results from XRX-OXY-101 Clinical Trial Jan 20
Investor sentiment improved over the past week Jan 17
XORTX Therapeutics Inc Files New Provisional Patent to Diagnose and Treat Individuals Most at Risk of Polycystic Kidney Disease Progression Jan 04
Investor sentiment improved over the past week Dec 30
XORTX Therapeutics Inc. Announces Completion of Dosing in XRX-OXY-101 Clinical Study Dec 20
XORTX Therapeutics Inc. Announces New Proof of Concept Data in Autosomal Dominant Polycystic Kidney Disease Dec 09
XORTX Announces Completion of Screening and Enrollment in Bridging Pharmacokinetics Study Nov 29
Investor sentiment deteriorated over the past week Nov 22
XORTX Therapeutics Appoints Stacy Evans as Chief Business Officer Nov 17
High number of new and inexperienced directors Nov 16
XORTX Therapeutics Inc. Receives Further No Objection Letter from Health Canada Oct 27 XORTX Therapeutics Inc. has completed a Composite Units Offering in the amount of $4.99964 million. Oct 06
XORTX Therapeutics Inc. Completes Positive Pre-Phase 3 Meeting with the US Food and Drug Administration Sep 20
Here's Why We're Watching XORTX Therapeutics' (CVE:XRTX) Cash Burn Situation Aug 23
XORTX Therapeutics Inc. Announces Positive Topline Results from Part 2 Pharmacokinetics Bridging Study Aug 23
High number of new and inexperienced directors Aug 03
XORTX Therapeutics Inc. Announces Submission to European Medicines Agency Jul 20
XORTX Therapeutics Inc. Announces Positive Topline Results from Pharmacokinetics Bridging Clinical Trial Jul 14
XORTX Announces Pre-Phase 3 Meeting Request with US Food and Drug Administration (FDA) Jul 08
XORTX Therapeutics Inc. Appoints Anthony Giovinazzo to the Board of Directors and as Chair of the Board Jun 07
XORTX Therapeutics Inc., Annual General Meeting, Jul 20, 2022 May 14
XORTX Therapeutics Inc. Opens an IND for XRx-008 Program for Autosomal Dominant Polycystic Kidney Disease May 08
XORTX Therapeutics Inc. Initiates Dosing of Human Subjects in the Xrx-Oxy-101 Clinical Trial May 05
XORTX Therapeutics Inc. announced delayed 20-F filing May 04
High number of new and inexperienced directors Apr 27 XORTX Therapeutics Inc. Receives No Objection Letter from Health Canada Apr 13
XORTX Therapeutics Inc. Announces Grant of US Patent Apr 08
Xortx Therapeutics Inc. Announces Filing of an Investigational New Drug Application with the Unites States Food and Drug Administration Apr 01
XORTX Therapeutics (CVE:XRTX) Is In A Strong Position To Grow Its Business Apr 01
XORTX Therapeutics Inc. Provides Corporate Update for 2022 Feb 01
XORTX Therapeutics Announces Filing of Provision Patent for Polycystic Kidney Disease Dec 22
We're Interested To See How XORTX Therapeutics (CVE:XRTX) Uses Its Cash Hoard To Grow Dec 16
XORTX Therapeutics Inc. Announces Publication of Mt. Sinai Study of Hospitalized COVID-19 Patients Dec 11
Companies Like XORTX Therapeutics (CSE:XRX) Can Afford To Invest In Growth Sep 01
XORTX Therapeutics Inc., Annual General Meeting, Apr 29, 2021 Mar 11
XORTX Therapeutics Inc. Announces the Filing of A New Provisional Patent Application Entitled "Compositions and Methods for Enhancing Anti-Viral Therapies" Mar 09
Independent Director exercised options to buy CA$91k worth of stock. Mar 04
XORTX Therapeutics Inc. announced that it has received CAD 6.121572 million in funding Feb 11
XORTX Therapeutics Inc. announced that it expects to receive CAD 3 million in funding Jan 09
New 90-day high: CA$0.22 Jan 05
XORTX Announces Grant of European Patent Dec 30
XORTX Therapeutics Inc. Announces Topline Results from Mount Sinai’s COVID-19 Clinical Study Nov 17
XORTX Therapeutics Inc. Receives Positive Feedback from FDA on COVID-19 Related Acute Kidney Injury Oct 10
New 90-day high - CA$0.27 Aug 21
New 90-day high - CA$0.21 Aug 05 Shareholder Returns XRTX CA Pharmaceuticals CA Market 7D 6.3% 2.3% -0.3% 1Y -54.0% -31.7% 15.7%
See full shareholder returns
Return vs Market: XRTX underperformed the Canadian Market which returned 15.7% over the past year.
Price Volatility Is XRTX's price volatile compared to industry and market? XRTX volatility XRTX Average Weekly Movement 14.0% Pharmaceuticals Industry Average Movement 12.3% Market Average Movement 8.2% 10% most volatile stocks in CA Market 17.4% 10% least volatile stocks in CA Market 3.0%
Stable Share Price: XRTX's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: XRTX's weekly volatility has decreased from 26% to 14% over the past year, but is still higher than 75% of Canadian stocks.
About the Company XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, pre-diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, a program to treat acute kidney injury (AKI) associated with respiratory virus infection and associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. It has a collaboration and license agreements with the Icahn School of Medicine; and a license agreement with the University of Florida Research Foundation, Inc. The company is based in Alberta Beach, Canada.
Show more XORTX Therapeutics Inc. Fundamentals Summary How do XORTX Therapeutics's earnings and revenue compare to its market cap? XRTX fundamental statistics Market cap CA$5.88m Earnings (TTM ) -CA$1.06m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) XRTX income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$736.66k Earnings -US$736.66k
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/02 21:10 End of Day Share Price 2024/12/30 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources XORTX Therapeutics Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution James Molloy Alliance Global Partners Chris Thompson eResearch Corporation
Show 0 more analysts 
